Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. (Nasdaq: CBUS) is an agricultural technology company that develops and licenses gene-edited plant traits to seed companies, with a focus on productivity traits for major row crops. The CBUS news page on Stock Titan aggregates company announcements, business updates, regulatory milestones, and collaboration news directly relevant to Cibus’ trait development and commercialization plans.
In its news releases, Cibus highlights progress in rice herbicide-tolerance traits HT1 and HT3, including material transfer agreements and a non-binding letter of intent with organizations and companies in Latin America to introduce these traits into elite rice germplasm and to prepare for commercialization in key rice-producing markets. The company also reports on collaborations aimed at bringing its gene editing technologies to India’s rice seed industry through strategic advisory partnerships.
News coverage for CBUS also includes updates on canola trait programs, such as positive field trial results for its HT2 herbicide-tolerance trait in North America and field trials for pod shatter reduction and disease resistance traits in winter oilseed rape. Additional items describe Cibus’ sustainable ingredients program, where the company has completed pre-commercial pilot runs for certain biofragrance products and received initial payments associated with commercialization efforts.
Investors and observers can use the CBUS news feed to follow Cibus’ participation in regulatory developments around gene editing in regions such as the European Union, the United Kingdom, North America and Ecuador, as well as corporate governance changes, board appointments, workforce adjustments and strategic focus updates. Regular visits to this page provide a consolidated view of how Cibus’ trait pipeline, partnerships and regulatory environment are evolving over time.
Cibus (NASDAQ:CBUS) has announced successful field trial results for its second-generation herbicide tolerance (HT2) edited Canola trait. The trials, conducted at multiple US locations during the 2025 growing season, validated the trait's performance under real-world conditions following positive greenhouse trials.
The HT2 trait offers enhanced weed management capabilities, allowing for fewer herbicide applications and compatibility with other herbicide resistance traits. This development demonstrates the effectiveness of Cibus' Rapid Trait Development System™ (RTDS®), which significantly reduces trait development time compared to conventional breeding or GMO approaches.
Cibus (Nasdaq: CBUS), an agricultural technology company focused on developing advanced plant traits, has announced the election of Kimberly A. Box to its Board of Directors. Box brings significant leadership experience from her roles as former CEO of Gatekeeper Innovation and VP of Global IT Services at Hewlett-Packard.
Box's appointment comes at a strategic time as Cibus prepares for the launch of its trait products. Her expertise in technology commercialization and scaling businesses will support the company's mission to improve farming productivity and sustainability. She currently serves on several boards including McGrath RentCorp and holds various certifications including NACD Directorship Certification™ and CERT in Cybersecurity Oversight.
Cibus (Nasdaq: CBUS), a leading agricultural technology company focused on gene-edited plant traits, announced that its Co-Founder, President, and Interim CEO Peter Beetham will participate in a panel discussion during UN Climate Week 2025 in New York City.
The panel, titled "Biotech Meet Bytes: Innovation and Policy Pathways for Resilient Futures," will explore how biotechnology, AI, and emerging technologies can enhance resilience in food, water, and energy systems. The session will take place on September 23rd at 3:35pm ET at Midtown Loft, with other panelists from UNDP and the World Bank.
Cibus (NASDAQ:CBUS), an agricultural technology company, has entered into a material transfer agreement with Centro Internacional de Agricultura Tropical (CIAT) to introduce its proprietary HT3 clethodim herbicide tolerance trait into elite rice germplasm for Latin America. The collaboration involves the Latin American Fund for Irrigated Rice (FLAR) and the Hybrid Rice Consortium for Latin America (HIAAL).
The agreement aims to develop high-performance rice hybrids with advanced weed control technology. Cibus' HT3 trait has shown strong performance in U.S. multi-location field trials across multiple seasons. The technology addresses challenges posed by herbicide-resistant weeds, including weedy rice, while supporting the development of climate-resilient, high-yielding rice varieties.
Cibus (NASDAQ:CBUS) reported Q2 2025 financial results and provided significant business updates. The company is streamlining operations to focus on Rice herbicide tolerance traits and partner-funded programs, aiming to reduce annual cash usage to $30 million by 2026.
Key developments include: commercialization of Rice herbicide tolerance traits HT1 and HT3 targeting Latin America launch in 2027 and U.S. expansion in 2028, with potential annual royalties exceeding $200 million; a new collaboration with Colombian Rice producer Semillano; and progress in sustainable ingredients programs expected to generate initial revenues in 2025.
Financial highlights: Q2 net loss of $26.6 million ($0.61 per share), cash position of $36.5 million, and successful completion of a $27.5 million public offering. The company expects current cash to fund operations into Q2 2026.
Cibus (Nasdaq: CBUS), an agricultural technology company specializing in plant trait development and licensing, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET the same day. Investors can access the call using U.S. dial-in (+1-833-316-2483) or International dial-in (+1-785-838-9284) with conference ID "CIBUS" or 24287. A replay will be available until August 28, 2025. The webcast and slides will be accessible through the investor section of Cibus' website for 90 days after the event.
Cibus (NASDAQ:CBUS), an agricultural technology company, announced a reduction in force (RIF) as part of implementing its streamlined business strategy. The company will focus on its nearest-term revenue opportunities, particularly in rice weed management traits and biofragrance products.
The restructuring will incur one-time charges of approximately $0.5 million in Q3 2025. Through these initiatives, Cibus aims to reduce its annual net cash usage to approximately $30 million by 2026. The company will prioritize its Trait Machine™ gene editing processes for HT1, HT3, and other trait combinations while maintaining customer-funded crop-based sustainable ingredients programs.
Cibus (NASDAQ: CBUS) has successfully completed the FDA's Plant Biotechnology Consultation Program for its altered lignin alfalfa trait, developed in partnership with S&W Seed Company. The FDA confirmed it has no further questions regarding the use of this gene-edited alfalfa in food or feed applications.
The altered lignin alfalfa offers two key benefits: potential improved digestibility for livestock and greater harvest timing flexibility for farmers. S&W Seed Company plans to commercialize two initial variety offerings - a fall dormancy five variety and a fall dormancy seven variety - marking the first commercial gene-edited alfalfa varieties in the United States.